AC Immune CEO to Showcase Novel Target Programs at UBS Global Healthcare Conference
Speaking on
In addition to the Company’s TDP-43 and alpha-synuclein targeting programs, the presentation will also detail advances for the clinical stage assets addressing the well-established pathophysiology mediated by Tau and Abeta. The critical role of the Company’s two proprietary platforms, SupraAntigen™ and Morphomer™, in fueling advances for antibodies and small molecules, respectively, will also be highlighted.
Date: May 20, 2020 | 9:10–10:00 am ET/ 3:10–4:00 pm CET
Format: Virtual presentation
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune SA
A webcast of the presentation will be available on the Events Page of AC Immune’s website.
About
AC
For further information, please contact:
Head of Investor Relations Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com |
US Media LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com |
Global Head of Communications Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com |
Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA